Media OutReach
SMART Launches New Research Centre to Develop World’s First Wearable Ultrasound Imaging System For Real-Time Monitoring of Chronic Conditions
- The Wearable Imaging for Transforming Elderly Care (WITEC) collaborative research project aims to develop the world’s first wearable ultrasound imaging system for continuous, real-time monitoring and personalised diagnosis of chronic conditions such as hypertension and heart failure.
- WITEC is a multi-million dollar, multi-year initiative that brings together top researchers from the Massachusetts Institute of Technology, Nanyang Technological University and the National University of Singapore, with Tan Tock Seng Hospital as its clinical collaborator.
- To support the research, WITEC is equipped with advanced tools such as Southeast Asia’s first Nanoscribe Quantum X sub-micrometre 3D printer and the most advanced Verasonics ultrasonic imaging system available in Singapore.
SINGAPORE – Media OutReach Newswire – 11 December 2025 – Imagine a world where ultrasound imaging is no longer confined to hospitals; patients with chronic conditions, such as hypertension and heart failure, could be monitored continuously in real time at home or on the move, giving healthcare practitioners ongoing clinical insights instead of the occasional snapshots – a scan here and a check-up there. This shift from reactive, hospital-based care to preventative, community and home-based care could enable earlier detection and timely intervention, and truly personalised care.
Bringing this vision to reality, the Singapore-MIT Alliance for Research and Technology (SMART), Massachusetts Institute of Technology’s (MIT) research enterprise in Singapore, has launched a new collaborative research project – Wearable Imaging for Transforming Elderly Care (WITEC).
WITEC marks a pioneering effort in wearable technology, medical imaging, research and materials science. It is Singapore’s first centre dedicated to foundational research and development of the world’s first wearable ultrasound imaging system capable of 48-hour intermittent cardiovascular imaging for continuous and real-time monitoring and diagnosis of chronic conditions such as hypertension and heart failure.
This multi-million dollar, multi-year initiative, supported by the National Research Foundation (NRF) Singapore under its Campus for Research Excellence and Technological Enterprise (CREATE) programme, brings together top researchers and expertise from MIT, Nanyang Technological University (NTU Singapore) and the National University of Singapore (NUS). Tan Tock Seng Hospital (TTSH) is WITEC’s clinical collaborator and will conduct patient trials to validate long-term heart imaging for chronic cardiovascular disease management.
“Addressing society’s most pressing challenges requires innovative, interdisciplinary thinking. Building on SMART’s long legacy in Singapore as a hub for research and innovation, WITEC will harness interdisciplinary expertise – from MIT and leading institutions in Singapore – to advance transformative research that creates real-world impact and benefits Singapore, the US and societies all over. This is the kind of collaborative research that not only pushes the boundaries of knowledge, but also redefines what is possible for the future of healthcare,” said Bruce Tidor, Chief Executive Officer and Director (Interim), SMART.
Industry-leading precision equipment and capabilities
To support this work, WITEC’s laboratory is equipped with advanced tools, including Southeast Asia’s first Nanoscribe Quantum X sub-micrometre 3D printer and the latest Verasonics Vantage NXT 256 ultrasonic imaging system, which is the first unit of its kind in Singapore.
Unlike conventional 3D printers that operate at millimetre or micrometre scales, WITEC’s 3D printer can achieve sub‑micrometre resolution, allowing components to be fabricated at the level of single cells or tissue structures. With this capability, WITEC researchers can prototype bioadhesive materials and device interfaces with unprecedented accuracy — essential to ensuring skin‑safe adhesion and stable, long‑term imaging quality.
Complementing this is the latest Verasonics ultrasonic imaging system. Equipped with a new transducer adaptor and supporting a significantly larger number of probe control channels than existing systems, it gives researchers the freedom to test highly customised imaging methods. This allows more complex beamforming, higher‑resolution image capture, and integration with AI‑based diagnostic models — opening the door to long‑duration, real‑time cardiovascular imaging not possible with standard hospital equipment.
Together, these technologies allow WITEC to accelerate the design, prototyping and testing of its wearable ultrasound imaging system, and to demonstrate imaging quality on phantoms and healthy subjects.
Transforming chronic disease care through wearable innovation
Chronic diseases are rising rapidly in Singapore and globally, especially among the ageing population and individuals with multiple long-term conditions. This trend highlights the urgent need for effective home-based care and easy-to-use monitoring tools that go beyond basic wellness tracking.
Current consumer wearables, such as smartwatches and fitness bands, offer limited physiological data like heart rate or step count. While useful for general health, they lack the depth needed to support chronic disease management. Traditional ultrasound systems, though clinically powerful, are bulky, operator-dependent, can only be deployed episodically within the hospitals, and are limited to snapshots in time — making them unsuitable for long-term, everyday use.
WITEC aims to bridge this gap with its wearable ultrasound imaging system that uses bioadhesive technology to enable up to 48 hours of uninterrupted imaging. Combined with AI-enhanced diagnostics, the innovation is aimed at supporting early detection, home-based pre-diagnosis and continuous monitoring of chronic diseases.
Beyond improving patient outcomes, this innovation could help ease labour shortages by freeing up ultrasound operators, nurses and doctors to focus on more complex care, while reducing demand for hospital beds and resources. By shifting monitoring to homes and communities, WITEC’s technology will enable patient self-management and timely intervention, potentially lowering healthcare costs and alleviating the increasing financial and manpower pressures of an ageing population.
Driving innovation through interdisciplinary collaboration
WITEC is led by the following Co-Lead Principal Investigators:
- Prof Xuanhe Zhao, Professor of Mechanical Engineering and Professor of Civil and Environmental Engineering, MIT
- Prof Joseph Sung, Senior Vice President (Health & Life Sciences), NTU Singapore, and Dean, Lee Kong Chian School of Medicine (LKCMedicine)
- Prof Cher Heng Tan, Assistant Dean, Clinical Research, LKCMedicine
- Prof Chwee Teck Lim, NUS Society Professor of Biomedical Engineering, NUS, and Director, Institute for Health Innovation and Technology, NUS
- Prof Xiaodong Chen, Distinguished University Professor, School of Materials Science & Engineering, NTU
“We’re extremely proud to bring together an exceptional team of researchers from Singapore and the US to pioneer core technologies that will make wearable ultrasound imaging a reality. This endeavour combines deep expertise in materials science, data science, AI diagnostics, biomedical engineering and clinical medicine. Our phased approach will accelerate translation into a fully wearable platform that reshapes how chronic diseases are monitored, diagnosed and managed,” said Prof Xuanhe Zhao, Co-Lead Principal Investigator, WITEC.
Research roadmap with broad impact across healthcare, science, industry and economy
Bringing together leading experts across interdisciplinary fields, WITEC will advance foundational work in soft materials, transducers, microelectronics, data science and AI diagnostics, clinical medicine and biomedical engineering. As a deep tech R&D, its breakthroughs will have the potential to drive innovation in healthcare technology and manufacturing, diagnostics, wearable ultrasonic imaging, metamaterials, and AI-powered health analytics. WITEC’s work is also expected to accelerate growth in high-value jobs across research, engineering, clinical validation and healthcare services, and attract strategic investments that foster biomedical innovation and industry partnerships in Singapore, the US and beyond.
“Chronic diseases present significant challenges for patients, families, and healthcare systems, and with aging populations such as Singapore, those challenges will only grow without new solutions. Our research into a wearable ultrasound imaging system aims to transform daily care for those living with cardiovascular and other chronic conditions – providing clinicians with richer, continuous insights to guide treatment, while giving patients greater confidence and control over their own health. WITEC’s pioneering work marks an important step towards shifting care from episodic, hospital-based interventions to more proactive, everyday management in the community,” said Prof Joseph Sung, Co‑Lead Principal Investigator, WITEC.
Led by Dr Violet Hoon, Senior Consultant at TTSH, the clinical trials are expected to commence in early 2026 to validate long-term heart monitoring in the management of chronic cardiovascular disease. Through innovations in bioadhesive couplants, nanostructured metamaterials and ultrasonic transducers, over the next three years, WITEC aims to develop a cart-based bioadhesive ultrasound (BAUS) system capable of continuous, real-time monitoring and personalised diagnosis of medical conditions. In future stages, WITEC aims to develop a fully integrated portable BAUS platform capable of 48-hour intermittent imaging.
As MIT’s research enterprise in Singapore, SMART is committed to advancing breakthrough technologies that address pressing global challenges. WITEC adds to SMART’s existing research endeavours that foster a rich exchange of ideas through collaboration with leading researchers and academics from the US, Singapore, and around the world in key areas such as antimicrobial resistance, cell therapy development, precision agriculture, AI and 3D-sensing technologies.
Hashtag: #SMART
The issuer is solely responsible for the content of this announcement.
About Singapore-MIT Alliance for Research and Technology (SMART)
Singapore-MIT Alliance for Research and Technology (
SMART) is MIT’s Research Enterprise in Singapore, established by the Massachusetts Institute of Technology (MIT) in partnership with the National Research Foundation of Singapore (NRF) since 2007. SMART is the first entity in the Campus for Research Excellence and Technological Enterprise (CREATE) developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore. Cutting-edge research projects in areas of interest to both Singapore and MIT are undertaken at SMART. SMART currently comprises an Innovation Centre and six Interdisciplinary Research Groups (IRGs): Antimicrobial Resistance (AMR), Critical Analytics for Manufacturing Personalized-Medicine (CAMP), Disruptive & Sustainable Technologies for Agricultural Precision (DiSTAP), Mens, Manus and Machina (M3S), Wafer-scale Integrated Sensing Devices based on Optoelectronic Metasurfaces (WISDOM), and Wearable Imaging for Transforming Elderly Care (WITEC).
SMART research is funded by the National Research Foundation Singapore under the CREATE programme.
For more information, please visit http://smart.mit.edu
About Wearable Imaging for Transforming Elderly Care (WITEC)
The WITEC collaborative research project is Singapore’s first centre dedicated to foundational research and development of wearable ultrasound imaging technology. Launched in May 2025 by the Singapore-MIT Alliance for Research and Technology (SMART), WITEC aims to pioneer the world’s first wearable ultrasound imaging system to enable continuous, real-time monitoring and personalised diagnosis of chronic conditions. By integrating advancements in soft materials, metamaterials, low-power electronics and intelligent algorithms, WITEC aims to shift healthcare from hospital-centric, reactive care to proactive, community-based solutions.
For more information, please visit https://smart.mit.edu/research/witec/about-witec
Media OutReach
MIMO: The AI-Native Storage Species Enables Desktop Scale AI Clusters With NVIDIA DGX Spark
- Engineered for the AI era, MIMO delivers breakthrough metrics: 400 GB/s bandwidth, 54 million IOPS, and 40–90 μs latency—all within a form factor comparable to a large suitcase.
- MIMO serves as both a high-performance data hub for large-scale GPU clusters and a flexible edge deployment platform, extending seamlessly to desktop environments where it orchestrates workflows with various DGX Spark units based on NVIDIA’s GB10 Grace Blackwell superchip.
- This architecture enables independent AI clusters supporting up to 16 computing nodes within constrained environments, managing the complete workflow from large-scale pre-training and fine-tuning to production inference—effectively democratizing enterprise-grade AI capabilities for labs, edge sites, and distributed teams.
SINGAPORE –
Professor Zhang Sheng from Tsinghua University Shenzhen International Graduate School expressed a more pragmatic view: “With this solution, we finally no longer have to rely on the university’s data center. Our current annual budget alone is enough to deploy an AI cluster within our lab that better fits our needs—this will significantly boost our research efficiency both technically and operationally. It’s truly fantastic news.”
Asia Debut Marks Industry Inflection Point
Earlier at the 8th China International Import Expo (CIIE), the solution’s core—the world’s first AI-native storage system MIMO—made its strategic Asian debut. Engineered for the AI era, MIMO delivers breakthrough metrics: 400 GB/s bandwidth, 54 million IOPS, and 40–90 μs latency—all within a form factor comparable to a large suitcase.
The platform’s defining Fast-Light-Edge proposition, delivered through its breakthrough architecture, cut through the exhibition noise, generating immediate and widespread attention. MIMO earned exclusive features in top-tier media including Hong Kong Ta Kung Pao and China Securities Journal, while its product demonstration videos gained rapid traction across leading digital channels.
Addressing Foundational Challenges: Technical Dialogues That Matter
During the exhibitions, technical leaders from the United States, Spain, Singapore, Colombia, the UAE (Dubai), India, Pakistan, and Hong Kong SAR engaged in substantive dialogues with Ridger’s Asia team, raising questions that revealed systemic industry gaps:
Architectural Transformation & Strategic Positioning
“Can MIMO fundamentally replace legacy storage architectures—traditional NAS, unified, distributed, and parallel file systems—to deliver accelerated parallel training and high-concurrency inference?”
“With such exceptional performance, would deploying MIMO for traditional enterprise applications represent strategic overinvestment or forward-looking infrastructure?”
Mobile Deployment & Borderless Operations
“MIMO’s suitcase-sized footprint suggests unprecedented mobility. Can it truly accompany research teams globally like standard equipment? How does it maintain operational continuity across jurisdictions? What’s the customs protocol for such ‘technical luggage’?”
Seamless Integration & Global Accessibility
“In scenarios with unnetworked AI servers, can MIMO rapidly establish dedicated training environments with true plug-and-play functionality?”
“Does MIMO integrate transparently with existing AI infrastructure and software stacks without requiring modifications?”
“Beyond Asia-Pacific, what’s the procurement pathway for MIMO? Which currencies and payment methods are accommodated?”
Architectural Breakthrough: Redefining What’s Possible
Addressing these operational realities, Ridger demonstrated MIMO’s system-level value—transcending its role as a storage device to become an architectural cornerstone. MIMO serves as both a high-performance data hub for large-scale GPU clusters and a flexible edge deployment platform, extending seamlessly to desktop environments where it orchestrates workflows with various DGX Spark units based on NVIDIA’s GB10 Grace Blackwell superchip.
Notably, eight global OEM partners—including Dell, HPE, Lenovo, xFusion, H3C, MSI, GIGABYTE, and Acer—have concurrently launched Spark versions based on NVIDIA’s GB10 Grace Blackwell superchip, creating a robust compatibility foundation for MIMO’s ecosystem integration.
This architecture enables independent AI clusters supporting up to 16 computing nodes within constrained environments, managing the complete workflow from large-scale pre-training and fine-tuning to production inference—effectively democratizing enterprise-grade AI capabilities for labs, edge sites, and distributed teams.
As Zhu Ting, an industry observer from Beijing, noted: “This represents the ‘IBM PC moment’ for AI infrastructure—transforming specialized capability into accessible utility.”
Market Validation Through Early Adoption
Market response has been decisive. Following the exhibitions, pioneering organizations across pathological image foundation model development, legal-tech innovation, industrial visual inspection, and naked-eye 3D content production have joined Ridger’s Early Access program, validating the architecture’s transformative potential in real-world operational contexts.
Global Rollout: Accelerating Accessibility
Responding to accelerating global demand, Ridger confirmed the imminent launch of the complete MIMO portfolio and optimized solution bundles for specific DGX Spark configurations through the Ridger Official Global Store. Designed as a frictionless procurement channel, the platform will support diverse payment options including multiple fiat currencies and cryptocurrencies—streamlining access to advanced AI infrastructure.
Organizations seeking deeper understanding of MIMO and its integrated lightweight AI solution with DGX Spark are invited to connect with Ridger team or its strategic partner, NVIDIA Elite Solution Partner SinoInfo.
Hashtag: #Technology #ESG #AI #GPU #Enterprise #Finance #Storage #Flash #Compute #DGX-Spark #NVIDIA #AI-Lab #GDS #NAS #AI-Native
https://ridger.tech/
https://www.linkedin.com/company/ridger/
https://www.youtube.com/@ridgertech
The issuer is solely responsible for the content of this announcement.
Ridger
Ridger is a global technology pioneer building next-generation computing & storage infrastructure for the AI era. Born in the East and operating worldwide, Ridger challenges conventional paths to create new technological paradigms.
The team unites seasoned experts from global storage leaders with visionary AI architects, all driven by a shared mission to democratize cutting-edge technology, rejects incremental improvements and hollow prestige, focusing exclusively on foundational breakthroughs that deliver tangible value and sustainable impact.
From architecture to implementation and from service to empowerment, Ridger provides end-to-end solutions that help clients worldwide ascend to their highest summits.
Media OutReach
Johnson & Johnson and Asia Pacific Patient Advocacy Group Leaders Unite to Strengthen Shared Decision-Making in Lung Cancer Care
J&J deepens its commitment to patient empowerment in Asia Pacific by launching J&J withMe, a new patient portal offering tailored patient resources, and co-driving market-specific initiatives with patient advocacy groups
SINGAPORE – Media OutReach Newswire – 11 December 2025 – Johnson & Johnson announced the next phase of The 3rd Opinion campaign across Asia Pacific, focused on championing shared decision-making between lung cancer patients and healthcare professionals through events and stakeholder engagements at ESMO Asia 2025 in Singapore.
At a Patient Reception on 6th December 2025, 20 leaders from 17 patient advocacy groups from across Asia Pacific, Europe and the United States shared their support for the need to strengthen shared decision-making. On December 7, 2025, the ESMO Asia 2025 Symposium, ‘Advancing EGFRm NSCLC Treatment Through Shared Decision-Making’ highlighted the role of healthcare professionals not only in making sense of the data but also in helping patients and their families navigate complex decision-making.
“High prevalence in Asia of certain NSCLC mutations makes the choice of first-line therapy absolutely critical. Treatment decisions must balance clinical objectives with patient values — weighing disease biology, survival prospects, durable disease control and the tradeoffs of side effects. That’s why shared decision-making is essential: clinicians should present all appropriate treatment options, so the final choice is collaborative and aligned with each patient’s goals,” said Professor Zhu Zhengfei, Director of the Radiation Oncology Department, Fudan University Shanghai Cancer Center.
“When lung cancer patients are empowered to speak up and understand their options, they are more likely to continue the treatment and their dignity is preserved. Initiatives like ‘The 3rd Opinion’ are vital for fostering truly patient-centered partnerships between people living with cancer and their healthcare teams,” noted Ms. Liu Yiting, Marketing & Branding Director, China MeetHealth Mi-Jian Patient Community.
“The shared commitment validates what many people living with lung cancer have long expressed: shared decision making is essential. From our experience supporting patients, meaningful conversations with clinicians help acknowledge patients’ experiences, address their concerns, and preserving their hopes,” added Mr. Jung-Il Cho, Chairman of Korea Lung Cancer Patients Association.
Our commitment comes off the back of a recent patient survey revealing that 90% of Japanese lung cancer patients want to play an active role in their treatment decisions. The survey also found that shared decision-making, where physicians and patients jointly compare treatment options and decide together, is the strongest driver of treatment satisfaction.1
Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction with their treatments, with 90% of lung cancer patients in Japan wanting to play an active role in their treatment decisions. This finding underscores the importance of shared decision-making and patient-centered care.1
To bridge the gap between patients’ desire to engage in shared decision making and their lack of practical support, J&J has launched “J&J withMe”, an online hub that equips lung cancer patients and caregivers with tailored toolkits and conversation guides to prepare for consultations and make informed, personalized treatment decisions.
Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific said, “The 3rd Opinion truly puts patients at the center of care. As part of our deep commitment to address patients’ unmet needs, we will continue partnering with patient advocacy groups and healthcare professionals to help patients to find their voice and the moment when medical advice meets what truly matters to patients.”
In recognition of diverse cultural and clinical norms across Asia Pacific, J&J has also rolled out tailored market activations in collaboration with local patient advocacy groups:
- Provision of patient resources such as the “Lung Cancer Book of Answers” in China, ‘Value of Time’ video for patients in Japan, and educational assets in India and Australia/New Zealand;
- Digital and social media engagement featuring patients and creators discussing the importance of shared decision-making across Singapore, Malaysia, Philippines, Thailand, and Vietnam;
- Event engagement via the establishment of a patient advisory board in India;
- Corporate Social Responsibility program with a lung cancer patient group in Korea, bringing employees and patients together to better understand the disease burden of patients and strengthen emotional support for the patient community.
###
About the 3rd Opinion
“The 3rd Opinion”, the patient’s own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.
About Non-Small Cell Lung Cancer
Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[1], [2] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[3] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[4] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[5], [6],[7],[8],[9],[10] EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[11] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.[12],[13] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[14] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[15]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[16].
[2] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.
Hashtag: #Johnson&Johnson
The issuer is solely responsible for the content of this announcement.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at 
https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.
Johnson & Johnson Innovative Medicine Asia Pacific, a division of Johnson & Johnson International (Singapore) Pte. Ltd is a Johnson & Johnson company.
© Johnson & Johnson International (Singapore) Pte. Ltd. [2025] All rights reserved.
Media OutReach
Skychakra Global Capital Strategy Upgrade: Advancing Cross-Border Listings and RWA Ecosystem
As a global hub for innovation and capital, Hong Kong serves as a significant gateway for the activation of Skychakra’s global strategy. This inauguration not only symbolizes the completion of the facility but also marks the comprehensive rollout of Skychakra’s international layout.
Official Launch of Cross-Border Listing Incubation Center
During the inauguration, Skychakra announced the establishment of a cross-border listing incubation center, led by a professional team qualified with SEC, PCAOB, and FINRA credentials, boasting over a hundred projects in cross-border listings. The service scope includes U.S. stocks, Hong Kong stocks, and SPACs. Unlike traditional investment banks and financial advisors, Skychakra offers a “full-link” service for enterprise capitalization, encompassing red-chip structure setup, financial and audit compliance, SEC and Hong Kong Stock Exchange filing guidance, dual-path IPO/SPAC design, market value management, enterprise internationalization guidance, and digital upgrades.
Originally planning to sign contracts for four companies at the conference, Skychakra exceeded expectations by signing 12, demonstrating its strong appeal and industry influence in cross-border listings and capital operations.
RWA Technology Ecosystem: Making Enterprise Assets Visible to the Financial System
Real World Assets (RWA) are becoming the core of global financial transformation. From BlackRock’s launch of tokenized funds to Hong Kong and Singapore incorporating RWA into financial infrastructure, RWAs are transitioning from concept to large-scale implementation. Skychakra emphasizes that small and medium-sized enterprises face common challenges such as lack of recognition for their assets within the financial system, difficulties in cross-border financing, and a lack of transparency in asset value.
The Skychakra RWA ecosystem will provide enterprises with: tokenizable asset identification, asset structuring and entitlement, on-chain mapping and minting, cross-border compliance design, global issuance and liquidity channels, and on-chain risk control and transparent tracking. The core value of RWA lies in reducing friction for enterprises in connecting to global capital, enhancing asset liquidity and valuation potential.
A Holistic Growth Model: “From People to Enterprises, From Enterprises to Capital”
Skychakra’s differentiated advantage stems from its foundational logic of “starting with people.” The Skychakra energy courses utilize scientific equipment to measure energy fields, emotional frequencies, and meridian states, assisting individuals in enhancing stability, insight, and decision-making abilities.
Based on this foundation, Skychakra constructs three major systems:
1. Enterprise Growth System: Enhancing organizational capabilities, introducing international business, and providing capital operation guidance.
2. Capitalization System: Building global financing capabilities through listings and RWA structures.
3. Asset Digitalization System: Making enterprise value quantifiable, verifiable, and tradable.
These three systems dynamically interact in a spiral structure, forming Skychakra’s unique full-link growth ecosystem.
Conclusion: Global Layout for Greater International Influence
The inauguration of Skychakra’s Hong Kong International Center signifies the official implementation of the group’s globalization strategy. Looking forward, the focus will be on Hong Kong as the core, with Asia as the main axis, while establishing deep collaborations with the North American and Middle Eastern markets. Through this global layout, Skychakra is creating a new organizational model that transcends regions, industries, and capital, enabling enterprises to achieve value flow in the global market and allowing more Asian companies to gain a stronger voice on the international stage.
Hashtag: #Skychakra
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking7 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn